Diabetes | Nueva Guía ADA 2025

Introduction to ADA 2025 Guidelines

Sponsorship and Overview

• This video is sponsored by Med Procesos, a company that supports medical professionals during their residency in Argentina, which offers over 5,000 positions annually based on admission exam scores.

• Viewers are encouraged to request free consultations through a link in the description and can receive a $100 discount if they mention "tutorías medicina interna."

Key Changes in ADA 2025 Guidelines

• The speaker notes that the new guidelines have become more extensive but also more tedious to read, potentially obscuring critical information for clinical practice.

• A significant recommendation includes continuous glucose monitoring for Type 2 diabetes patients, even those not using insulin—an update from previous guidelines.

• New evidence regarding GLP-1 receptor agonists highlights cardiovascular benefits related to heart failure and renal health. The discussion will include insights from relevant studies later on.

Diabetes Management Insights

Nutritional and Psychotherapeutic Approaches

• The updated guidelines emphasize improved nutritional management and psychotherapeutic strategies for diabetes care, including detailed discussions on language use in patient communication.

• There is an expanded section on hyperglycemic crises with comprehensive diagnostic criteria and management protocols introduced this year compared to previous versions of the guidelines.

Understanding Diabetes as a Global Epidemic

• Diabetes is defined as a group of conditions leading to impaired glucose metabolism, resulting in persistent hyperglycemia due to both underutilization and overproduction of glucose. This condition has reached epidemic levels worldwide.

• Statistics reveal that only half of diabetes patients achieve target HbA1c levels; when considering LDL cholesterol and blood pressure targets, compliance rates drop significantly further. This indicates high morbidity/mortality associated with uncontrolled diabetes.

Chronic Care Models for Diabetes

Importance of Patient-Centered Care

• Implementing chronic care models focused on patient-centered approaches has been shown to reduce medical complications and healthcare costs significantly—highlighted by annual costs reaching $413 billion in the U.S. alone due to diabetes-related issues.

Role of Technology in Diabetes Management

• Telemedicine is emphasized as a crucial tool for increasing accessibility to care among diabetic patients while ensuring specialist involvement; currently, only 9% of U.S.-based diabetes patients consult endocrinologists regularly despite many needing such expertise at least annually.

Social Determinants Affecting Diabetes Control

Addressing Social Factors

• The discussion includes social determinants affecting health outcomes such as food security, housing stability, migrant status, language barriers, and low health literacy—all critical factors influencing disease management effectiveness among diabetic populations.

Industry Involvement in Medication Pricing

• The speaker advocates for industry engagement in strategies aimed at reducing medication prices—a necessary step given the high out-of-pocket costs faced by patients with chronic illnesses like diabetes due to poor regulatory environments in some countries (e.g., Colombia).

Classification of Diabetes Mellitus

Types of Diabetes

• Diabetes mellitus is classified into four categories: Type 1 (autoimmune), Type 2 (most common due to insulin resistance), specific causes, and gestational diabetes; there are no recognized types three or four within this classification system yet discussed here.

Understanding Diabetes Classification and Management

Overview of Diabetes Types

• Discussion on specific disorders such as monogenic diabetes and exocrine pancreatic disorders, including chronic pancreatitis and cystic fibrosis, which can be drug-induced.

• Emphasis on the need for improved classification systems that go beyond simplistic categorizations (Type 1 vs. Type 2) to include genetic, metabolomic, and pathophysiological implications.

Challenges in Differentiating Diabetes Types

• Difficulty in distinguishing between Type 1 and Type 2 diabetes; previously thought to be clear-cut based on age and body type.

• Notably, around 40% of adults with Type 1 diabetes may be misclassified as having Type 2 diabetes due to overlapping characteristics.

Diagnostic Criteria for Diabetes

• Importance of recognizing that Type 1 diabetes can present later in life; differentiation is crucial since Type 2 can also show autoimmune markers.

• Introduction of the "Triple A" acronym for differentiating types:

• Age: Under 35 years suggests possible Type 1.

• Body Mass Index (BMI): Less than 25 indicates potential Type 1.

• Control: Insulin dependency points towards an autoimmune etiology.

Pathophysiology of Diabetes

• The multifactorial nature of Type 2 diabetes includes both genetic predispositions and environmental factors leading to a gradual disease progression.

• Common hyperglycemic crises differ between types; hyperosmolar hyperglycemic state is more typical for Type 2 while ketoacidosis is associated with Type 1.

Risk Factors and Screening Recommendations

• Key risk factors for developing Type 2 diabetes include metabolic syndrome components like hypertension, dyslipidemia, obesity, along with significant genetic contributions.

• Discussion on the relationship between periodontal disease and diabetes; screening recommendations suggest monitoring individuals over age 30 who visit dental health services.

Targeted Screening Guidelines

• Recommended screening for those with obesity or overweight status alongside other risk factors such as family history or ethnic background linked to higher risks.

• Specific guidelines indicate annual screenings starting at age 35 or earlier if prediabetes is detected; additional considerations include patients on certain medications like corticosteroids or antipsychotics.

Testing Methods for Diabetes Diagnosis

New Guidelines on Diabetes Management and Screening

Introduction of Risk Score for Diabetes Screening

• The discussion introduces a new risk score that could be implemented in diabetes recommendations, suggesting that patients with a score of five or more should undergo screening.

Remission Possibilities in Diabetes

• Recent interventions such as intensive nutritional changes, exercise, GLP-1 medications, and metabolic surgery are now recognized for potentially leading to disease remission.

• Previously, remission was only associated with metabolic surgery; however, the new guidelines suggest effective management can also lead to remission.

Identifying Prediabetes

• Prediabetes is identified through specific hemoglobin A1c levels (5.7% - 6.4%), fasting glucose (100 - 125 mg/dL), or an oral glucose tolerance test (OGTT) result between 140 - 200 mg/dL.

• Patients with prediabetes are at higher risk for progression to diabetes and cardiovascular diseases, thus benefiting from cardiovascular risk screening.

Confirming Diabetes Diagnosis

• A diabetes diagnosis is confirmed when hemoglobin A1c is above 6.5%, fasting glucose is ≥126 mg/dL, or OGTT results are ≥200 mg/dL; two abnormal results are typically required for confirmation.

• If one test shows abnormal results while another does not, the abnormal test must be repeated to confirm the diagnosis.

Immediate Diagnosis Scenarios

• An immediate diabetes diagnosis can occur if a patient has random blood glucose >200 mg/dL along with symptoms like polyuria, polydipsia, polyphagia, or weight loss without needing further confirmation.

Testing Considerations and Recommendations

• The OGTT is highlighted as having the best performance for diagnosing diabetes but requires proper preparation including an overnight fast and carbohydrate intake prior to testing.

Limitations of Hemoglobin A1c Testing

• While hemoglobin A1c testing is convenient and reproducible without daily variations due to stress or illness, it may be less sensitive than OGTT and affected by conditions altering red blood cell lifespan.

Current Recommendations on Testing Methods

• The latest guidelines suggest considering both hemoglobin A1c and OGTT based on individual circumstances rather than favoring one over the other outright.

Cost Considerations in Testing

• Hemoglobin A1c tests tend to be more expensive than OGTT; however, they provide valuable insights into average glucose levels over time.

Conditions Affecting Test Results

Understanding Diabetes: Type 1 and Type 2

Overview of Diabetes Testing Alternatives

• The discussion begins with the exploration of alternative tests for diabetes diagnosis, such as fructosamine and glycosylated albumin, which are currently less available.

Insights into Type 1 Diabetes

• Type 1 diabetes accounts for approximately 5-10% of all diabetes mellitus cases and is classified as an autoimmune condition characterized by specific autoantibodies. The three main autoantibodies include GAD65, IA-2, and IAA.

• Genetic and environmental factors contribute to the risk of developing type 1 diabetes, including autoimmune syndromes, infections (like COVID-19), certain medications (e.g., immunotherapy), and obesity.

Associated Autoimmune Conditions

• Patients with type 1 diabetes often have other autoimmune diseases such as Hashimoto's thyroiditis, celiac disease, Addison's disease, vitiligo, and myasthenia gravis. It is noted that about 10% of individuals with these conditions may also develop type 1 diabetes.

Screening Recommendations

• Screening for type 1 diabetes should be considered in at-risk populations—those with family history or genetic predisposition—by testing for autoantibodies. A positive result for two autoantibodies indicates a 70% chance of developing the disease within ten years. Confirmatory testing is recommended after three months due to potential transient positivity following events like pancreatitis.

Current Guidelines on Screening Practices

• While some countries like Italy recommend screening alongside celiac disease testing, there is no formal recommendation yet due to insufficient evidence supporting universal screening for type 1 diabetes in the general population. Management should involve a team of specialists familiar with the evolving pathophysiology of this condition.

Stages of Type 1 Diabetes Development

• The progression through stages of type 1 diabetes includes:

• Stage One: Autoimmunity present but normal blood glucose levels.

• Stage Two: Autoimmunity with dysglycemia but no symptoms.

• Stage Three: Clinical manifestation of type 1 diabetes.

Notably, only a minority progress from stage one to three within five years; thus early identification is crucial to prevent severe complications like diabetic ketoacidosis (DKA). Regular monitoring through HbA1c tests every six months and oral glucose tolerance tests annually is advised.

Diagnostic Challenges in Adult Onset Cases

• In adults presenting atypically (e.g., age over 40) who meet criteria suggesting possible type one diagnosis despite negative autoantibody tests (noting that about 10% may not show these antibodies), further evaluation should consider monogenic forms or characteristics indicative of type two diabetes based on family history or clinical presentation. If C-peptide levels are low (<200 pmol/L), it suggests type one; higher levels necessitate further investigation into genetic causes or other types if they fall between thresholds indicating uncertainty regarding classification.

Prevention Strategies

Nutrition and Diabetes Management

Nutritional Strategies for Weight Management

• Approximately 7-10% of body weight loss can significantly reduce diabetes risk by 16%. Emphasis on nutritional management through Mediterranean diet, DASH diet, and plant-based eating is crucial.

• The ketogenic diet is discouraged due to its association with increased cardiovascular risk. Instead, focus on dietary patterns rather than specific macro or micronutrient values.

Importance of Nutrient-Dense Foods

• Recommendations highlight the consumption of nutrient-dense foods that are low in calories but high in essential nutrients. This approach supports overall health without excessive caloric intake.

Role of Sleep Hygiene

• Sleep hygiene is emphasized as a critical factor; both insufficient (<6 hours) and excessive (>9 hours) sleep increase diabetes risk. Proper sleep management should be integrated into preventive programs.

Exercise Recommendations

• Regular physical activity is vital; patients should aim for 150 minutes of moderate-intensity aerobic exercise weekly, supplemented by strength training (75 minutes). Young patients may substitute this with high-intensity workouts.

• Caution regarding hypoglycemia during exercise in type 1 and type 2 diabetes patients is necessary, especially those requiring insulin. Potential complications from vigorous exercise must also be considered.

Monitoring and Medication Use

• Metformin is the only formally recommended medication for prediabetes management, particularly effective in individuals aged 25 to 60 with a BMI ≥35 and elevated glycemic parameters.

Cardiovascular Risk Management

Comorbidities in Prediabetes

• Managing cardiovascular risks alongside diabetes prevention is essential since type 2 diabetes often coexists with multiple metabolic comorbidities. A comprehensive approach improves patient outcomes.

Statins and Diabetes Risk

• While statins may slightly increase the risk of developing type 2 diabetes, their benefits outweigh these risks. Discontinuing statin therapy solely based on prediabetes status is not advisable.

Smoking Cessation Importance

• Smoking cessation plays a significant role in reducing diabetes risk; all forms of tobacco use (including vaping and marijuana smoking) should be minimized or avoided entirely.

Advanced Treatment Options

Pioglitazone Considerations

• In prediabetic patients who have experienced an acute coronary event (ACE), pioglitazone may be considered to prevent progression to type 2 diabetes despite potential adverse effects like fractures or edema.

Type 1 Diabetes Interventions

Understanding Diabetes Management

Evidence for Type 1 Diabetes Progression

• The progression probability of Type 1 diabetes lacks substantial evidence; most risk management strategies discussed apply to Type 2 diabetes or prediabetes.

• Current recommendations emphasize the importance of exercise as a key intervention for managing Type 1 diabetes.

Initial Patient Evaluation

• Upon diagnosing a patient with diabetes, it is crucial to assess their risk for complications, including cardiovascular issues and metabolic conditions like retinopathy and neuropathy.

• Establishing treatment goals is essential, focusing on hemoglobin A1c levels and hypertension management.

• A comprehensive management plan should include both pharmacological and non-pharmacological approaches, along with appropriate referrals to specialists when necessary.

Patient-Centered Care Approach

• Throughout the diagnostic process, patient inclusion is vital; treatment objectives should align with the patient's personal goals and preferences.

• It’s important to use non-stigmatizing language when referring to patients living with diabetes, avoiding terms that may imply judgment or bias against their condition.

Self-Management Education and Support (DMES)

• DMES empowers patients by enhancing their self-management skills, enabling them to recognize when they need help or adjustments in their care regimen.

• There are five critical moments for reinforcing DMES: at diagnosis, annually, when goals are not met, during complications, and during life transitions (e.g., adolescence to adulthood).

Monitoring Glycemic Control

• After establishing initial management plans for diabetic patients, regular monitoring of glycemic status through hemoglobin A1c tests or continuous glucose monitoring (CGM) is recommended at least twice a year.

• The general target for hemoglobin A1c is set at 7%, correlating with specific blood glucose ranges before and after meals (80–130 mg/dL preprandial; <180 mg/dL postprandial).

Continuous Glucose Monitoring Insights

• CGM provides a more comprehensive view of glycemic control over time by measuring interstitial glucose levels continuously over two weeks. This method allows better assessment of daily fluctuations in blood sugar levels compared to traditional methods.

Understanding Glycemic Control in Diabetes Management

Importance of Glycemic Targets

• The recommended glycemic targets for older adults should be less than 4% or 1%, with a TBR (Time Below Range) under 54% not being acceptable in this demographic.

• Continuous glucose monitoring can help adjust treatment based on daily patterns, particularly noting that hypoglycemia often occurs during the night.

• Individualized glycemic targets are crucial; for example, an 8% target may be suitable for older patients with multiple comorbidities, while younger patients might aim for a lower target of 6.5%.

Factors Influencing Glycemic Goals

• Key factors influencing hemoglobin A1c (HbA1c) goals include diabetes duration, risk of hypoglycemia, and other comorbidities.

• Regular assessment of hypoglycemia risk is essential; some patients may not recognize symptoms due to chronic exposure to low blood sugar levels.

• Episodes of severe hypoglycemia necessitate reevaluation of management plans and treatment goals.

Impact of HbA1c Levels on Complications

• Maintaining an HbA1c below 7% has been shown to reduce microvascular complications such as neuropathy, retinopathy, and nephropathy.

• While evidence for macrovascular complication reduction in Type 2 diabetes is lacking, Type 1 diabetes shows benefits from good glycemic control.

Initiating Pharmacological Management

• After establishing a clear understanding of patient needs and risks, pharmacological management can begin alongside non-pharmacological strategies.

• When initiating medication for diabetes type two, considerations include cardiovascular events and potential side effects related to renal function and metabolism.

Medication Considerations Based on Patient Profile

• Key questions before starting pharmacotherapy include assessing cardiovascular disease risk, heart failure status, and presence of obesity or metabolic liver disease.

• Patients at high cardiovascular risk benefit from GLP-1 receptor agonists or SGLT2 inhibitors due to their proven cardiovascular protective effects.

• In cases of heart failure or chronic kidney disease (CKD), specific SGLT2 inhibitors show efficacy in both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF).

Recent Developments in Diabetes Medications

• New studies have emerged demonstrating the cardiovascular benefits associated with certain medications like semaglutide oral formulations.

GLP-1 and Diabetes Management

Importance of GLP-1 Analogues in Obesity and Liver Health

• The speaker emphasizes the significance of GLP-1 analogues for obesity management, while pioglitazone is noted specifically for hepatic steatosis.

New Recommendations for Type 2 Diabetes Management

• New recommendations highlight that GLP-1 analogues benefit adults with type 2 diabetes and heart failure with preserved ejection fraction by reducing related symptoms.

• Combining pioglitazone with GLP-1 can be considered for patients with biopsy-proven liver fibrosis, as studies show a reduction in fibrosis.

• For cardiovascular risk reduction and chronic kidney disease progression in diabetic patients, GLP-1 analogues have demonstrated benefits, particularly semaglutide.

Treatment Algorithm for Type 2 Diabetes

• The treatment approach begins with non-pharmacological management (education, social determinants assessment), followed by pharmacological options based on specific patient conditions.

• If a patient has cardiovascular disease or high risk, an SGLT2 inhibitor or GLP-1 analogue is recommended; if they have heart failure, SGLT2 inhibitors are preferred.

Dual Therapy Considerations

• Initiating dual therapy is advised when a patient's HbA1c is significantly above target (e.g., >8.5%); ideally including a GLP-1 analogue or tirzepatide.

• Insulin therapy should be initiated for patients presenting with HbA1c >10%, blood glucose >300 mg/dL, or signs of beta-cell failure.

Injectable Medications Overview

• In cases where injectable medications are indicated due to inadequate glycemic control despite oral medications, preference should be given to GLP-1 analogues over insulin unless HbA1c exceeds 10%.

Insulin Preferences

• When considering insulin initiation, second-generation insulins like glargine U300 are preferred due to lower hypoglycemia risks compared to first-generation insulins.

New Guidelines on Inhaled Insulin

• Recent guidelines now recommend inhaled insulin as comparable to rapid-action insulins; it does not contribute to weight gain unlike traditional insulins.

Insulin Types and Administration Strategies

Overview of Insulin Types

• The discussion begins with the classification of insulin types: short-acting (regular human insulin), intermediate-acting (NPH), and long-acting insulins such as degludec and glargine, which are considered second-generation.

• Pre-mixed insulins combining GLP-1 receptor agonists with basal or prandial insulins are also mentioned, highlighting their role in diabetes management.

Initiating Insulin Therapy

• A common concern is how to initiate insulin therapy for patients. It is recommended to consider GLP-1 receptor agonists first, especially when combined with insulin.

• When using combinations like Soliqua or Eglu, the dosage of GLP-1 is lower than in studies demonstrating cardiovascular benefits due to the influence of insulin units on dosing.

Patient Assessment for Insulin Needs

• If a patient has not improved on two or three oral medications, it’s crucial to assess if they have been prescribed a GLP-1 agonist; if not, it should be considered.

• For patients needing insulin, basal (once or twice daily) and prandial (before meals) options are discussed. Starting doses typically begin at 10 units or 0.1–0.2 units per kilogram.

Monitoring and Adjusting Insulin Doses

• Patients starting on insulin must use a glucometer for monitoring blood glucose levels before meals and at night. Adjustments should be made based on readings above 130 mg/dL after three days.

• If hypoglycemia occurs, reduce the dose by 10% to 20%. Regular follow-ups every three months are essential for evaluating hemoglobin A1c levels.

Evaluating Over-Basal Insulin Needs

• Persistent high hemoglobin A1c levels may indicate over-basal needs; adjustments might include adding preprandial insulin while maintaining basal doses.

• Initial preprandial doses can start at four units or 10% of the basal dose. If A1c remains above target but below eight, consider reducing basal before adding preprandial doses.

Advanced Insulin Regimens

• If hemoglobin A1c continues to exceed targets after initial adjustments, additional bolus injections may be added before meals up to three times daily—this regimen is known as multiple daily injections (MDI).

Managing Type 1 Diabetes

Understanding Type 1 Diabetes Management

• Patients with type 1 diabetes require consistent administration of insulin due to an absolute deficiency caused by destruction of pancreatic beta cells.

Delivery Methods for Insulin

Diabetes Management for Type 1 Patients

Key Challenges in Managing Type 1 Diabetes

• The primary issue for patients with type 1 diabetes is the high cost of treatment, which often limits access to necessary tools like insulin pumps.

• Education is crucial; patients must understand carbohydrate counting and how to adjust their insulin doses based on this knowledge, unlike type 2 diabetes patients who may have fixed bolus doses.

Insulin Administration Techniques

• Preference should be given to insulin analogues or inhaled insulin when using injections. Continuous glucose monitoring (CGM) is recommended for all type 1 diabetes patients.

• There are ongoing discussions about the potential benefits of GLP-1 agonists and SGLT2 inhibitors in managing blood sugar levels, but no definitive recommendations exist yet.

Tools and Applications for Education

• Various applications can assist with carbohydrate counting and understanding insulin sensitivity; "Diabetes M" is highlighted as a useful tool.

• Patients experiencing severe hypoglycemia or ketoacidosis despite intensive insulin therapy may be candidates for pancreatic beta-cell transplants.

Technological Advances in Diabetes Management

• Technology aims to provide more physiological and adaptive insulin delivery systems, improving glycemic control through devices like glucose meters and continuous glucose monitors (CGMs).

• Evidence shows that technology improves glycemic control while reducing hypoglycemia risk, although it requires significant education and increases management costs.

Monitoring Blood Glucose Levels

• All patients on multiple daily injections of insulin should use glucose meters; however, evidence supporting glucometry's effectiveness in type 2 diabetes remains limited.

• Continuous glucose monitors come in various types: real-time monitors continuously assess interstitial glucose levels, while intermittent monitors require manual data retrieval every few minutes.

Recommendations for Continuous Glucose Monitoring

• CGM should be recommended for all patients on multiple daily injections at risk of hypoglycemia, including pregnant women.

• While ideal scenarios suggest universal CGM implementation, practical constraints limit its application primarily to those needing closer monitoring due to frequent hypoglycemic episodes.

Benefits of Continuous Glucose Monitoring

Insulin Pumps and Continuous Glucose Monitoring

Overview of Insulin Delivery Systems

• Insulin delivery systems can be affected by various substances, such as vitamin C and acetaminophen. It's crucial to monitor these interactions.

• Insulin pumps provide continuous infusion of rapid-acting insulin, mimicking the pancreas's natural insulin release into the bloodstream.

• Hybrid closed-loop systems integrate sensors that alert users about glucose trends, allowing for automatic adjustments in insulin delivery based on predicted hypoglycemia.

• The fully closed-loop system operates autonomously with integrated devices and algorithms, representing a true artificial pancreas.

• Ideal candidates for these systems include all type 1 diabetes patients and some type 2 patients at high risk for hypoglycemia.

Patient Management and Follow-Up

• Annual screenings for diabetes complications and cardiovascular risks are essential; however, clinical practice may prioritize different aspects based on individual patient needs.

• Regular evaluations should include adherence to treatment plans, risk assessment for hypoglycemia, immunizations, and screening for autoimmune conditions related to diabetes.

• Patients with diabetes have a significantly higher risk (43 times more likely) of developing dementia; thus, managing hypoglycemia is critical to prevent cognitive decline.

• Consideration of comorbidities like obesity, psychiatric components, periodontal disease, and sexual dysfunction is vital in comprehensive patient care.

Addressing Obesity in Diabetes Management

• Obesity is defined as a BMI over 30 (27 for Asian populations), but it requires a complete nutritional assessment beyond just BMI measurements.

• Managing obesity is crucial as it prevents the development of type 2 diabetes and cardiovascular diseases; annual evaluations are recommended.

• A weight loss goal of 3% to 7% can improve health outcomes; ideally aiming for over 10%, guided by nutritionists or exercise specialists.

• Effective management includes creating a caloric deficit of 500 to 700 calories daily while monitoring medication impacts on weight maintenance.

Management of Weight Loss and Metabolic Surgery

Importance of Balanced Diets

• Emphasizes the need for maintaining weight loss through balanced diets rather than ultra-restrictive, low-calorie diets, which should only be considered temporarily and for selected patients.

Nutritional Supplements and Devices

• Highlights the lack of evidence supporting nutritional supplements and discusses various devices that serve as intermediaries between metabolic surgery and pharmacological management, such as gastric balloons and vagus nerve stimulators.

Pharmacological Management

• Discusses pharmacological interventions for patients with a body mass index (BMI) over 27 who do not achieve weight reduction through lifestyle changes. Medications include GLP-1 agonists and SGLT2 inhibitors, pending FDA approval.

Indications for Metabolic Surgery

• Indicates that metabolic surgery is recommended for patients with a BMI over 30 who fail to lose weight despite pharmacological treatment and lifestyle modifications.

Multidisciplinary Approach in Surgery

• Stresses the importance of a multidisciplinary team in managing metabolic surgery due to its effectiveness in inducing remission in over 80% of diabetes cases while also addressing potential complications.

Psychological Considerations

• Underlines the necessity of psychiatric evaluations to ensure patients are mentally prepared for the significant lifestyle changes required post-surgery.

Cardiovascular Risk Management

• Discusses cardiovascular risk management alongside glycemic control, emphasizing regular assessments based on regional guidelines to categorize patient risk levels effectively.

Hypertension Screening Guidelines

• Recommends screening for hypertension every six months using specific definitions from ADA guidelines, aiming for blood pressure targets based on recent studies demonstrating benefits from strict control.

Treatment Strategies Based on Hypertension Levels

• Outlines treatment strategies depending on hypertension severity; recommends combination therapy if blood pressure exceeds certain thresholds while considering albuminuria status when selecting medications.

Dyslipidemia Management Approaches

Statin Management and Cardiovascular Risk

Statin Use in Dyslipidemia

• Emphasizes the importance of appropriate management of high-intensity statins, with target LDL levels set at 70 mg/dL for primary prevention and 55 mg/dL for secondary prevention.

• Discusses initiating statin therapy based on triglyceride levels, recommending treatment if levels exceed 150 mg/dL in patients with cardiovascular risk or above 500 mg/dL without such risk to prevent pancreatitis.

Antiplatelet Therapy Guidelines

• Notes that all patients with atherosclerotic disease should be prescribed aspirin or other antiplatelet agents; dual therapy is indicated post-revascularization.

• Suggests considering aspirin in primary prevention for high-risk patients aged 50-70 years with low bleeding risk, referencing supportive studies.

Screening Recommendations

• Clarifies that routine coronary artery screening (e.g., CT angiography) is not recommended for diabetic patients without symptoms but emphasizes rapid assessment if symptoms arise.

• Recommends screening all diabetic patients for heart failure using natriuretic peptide measurements and echocardiography if elevated.

Peripheral Arterial Disease Assessment

• Advises screening for peripheral arterial disease using ankle-brachial index in all diabetic patients over 65 years old or those with microvascular complications after ten years of diabetes duration.

Management Strategies in Cardiovascular Disease

Pharmacotherapy Considerations

• Highlights the use of GLP-1 receptor agonists and SGLT2 inhibitors as non-exclusive options for managing cardiovascular disease in high-risk patients.

• Recommends ACE inhibitors and beta-blockers as standard treatments in coronary artery disease cases, especially when proteinuria is present.

Diabetes Management Insights

• Stresses the initiation of ICAR2 therapy for all diabetes patients over 55 years old with cardiovascular risks, regardless of existing cardiovascular conditions.

Hepatic Steatosis and Diabetes

Screening and Evaluation Protocol

• Underlines the need to educate type 1 and type 2 diabetes patients about ketoacidosis risks when starting SGLT2 inhibitors.

• Discusses the importance of evaluating hepatic steatosis through non-invasive fibrosis scoring (FIB4), recommending further action based on results.

Treatment Options Based on Fibrosis Stage

• Indicates that more than 70% of type 2 diabetes patients have hepatic steatosis; thus, pharmacotherapy must address both diabetes management and potential therapies targeting liver health.

Fracture Risk Associated with Diabetes

Osteoporosis Considerations

• Notes that diabetes mellitus increases osteoporosis risk due to general factors; recommends ensuring adequate calcium and vitamin D intake while preventing hypoglycemia to reduce fall risks.

Osteopenia and Diabetes Management

Pharmacological Management in Osteopenia

• The discussion emphasizes the importance of considering pharmacological management for osteopenia, particularly in patients with diabetes mellitus, which is noted to have a higher bone mineral density but lower bone strength.

Risk Assessment Adjustments

• It is recommended to add 0.5 to the bone mineral density results from densitometry for categorization purposes in diabetic patients. Additionally, rheumatoid arthritis is considered equivalent to diabetes mellitus when assessing risk using the FRAX calculator.

Screening Recommendations

• Patients over 65 years with diabetes should be screened for osteopenia and osteoporosis. Women post-menopause and men over 50 with specific fracture histories or diabetes-related risk factors should also undergo screening.

Mental Health Considerations

• Referral to psychiatry should occur if there are signs of depressive symptoms or intentional medication omission by the patient, indicating potential mental health issues.

Vaccination Protocols

• Vaccinations such as COVID-19, hepatitis B, influenza, and pneumonia are crucial for these patients. Specific vaccines like PCV20 and RSV should also be included in their vaccination schedule.

Hospitalization Protocol for Diabetic Patients

Initial Glucose Monitoring

• Upon admission of a diabetic patient to an emergency service, glucometry must be performed immediately. If glucose levels exceed 140 mg/dL, further tests including hemoglobin A1c should follow.

Insulin Management During Hospitalization

• For patients already on insulin therapy (especially basal-bolus regimens), insulin administration should not wait until hyperglycemia occurs; it must start upon admission based on prior treatment plans.

Intrahospitalary Insulin Regimen

• Insulin management during hospitalization will typically involve a basal-bolus or basal-plus regimen tailored according to blood glucose readings. Corrective doses may also be applied based on individual glucose levels.

Target Glucose Levels

• The target glucose range during non-critical scenarios is set between 140 to 180 mg/dL. Continuous monitoring before meals and at night is essential for effective management.

Use of Oral Medications

Management of Diabetes in Surgical Patients

Nutritional Management and Corticosteroids

• If nutrition is suspended for a patient on continuous nutrition, initiate destrosa to prevent hypoglycemia.

• The use of corticosteroids depends on their type; short-acting corticosteroids like methylprednisolone require NPH dosing alongside the regular patient regimen.

• For long-acting corticosteroids such as dexamethasone, adjust the patient's basal insulin regimen as needed. Continuous management is possible if the patient can handle their diabetes technology effectively.

Preoperative Considerations

• Pre-anesthetic evaluation is essential; ideally, patients should have an HbA1c below 8% before surgery.

• Intraoperative blood glucose targets should be maintained between 100 to 180 mg/dL. Most oral antidiabetic medications are continued except on the day of surgery; SGLT2 inhibitors should be stopped four days prior, and GLP-1 analogs may need suspension seven days post-surgery due to nausea risk.

Postoperative Management

• Discharge planning relies heavily on HbA1c levels:

• Below 7%: continue current management.

• Above 10%: initiate insulin therapy with a basal-bolus approach.

• Between 7% and 8%: consider oral antihyperglycemics.

• Between 8% and 10%: prefer GLP-1 or combined therapies with oral agents or insulin where feasible.

Complications of Diabetes

Acute vs Chronic Complications

• Diabetes complications can be acute (hyperglycemic crises) or chronic (microvascular/macrovascular). Acute complications include hyperglycemia and hypoglycemia, while chronic issues develop over time post-diagnosis—five years for Type 1 and annually for Type 2 from diagnosis.

Hyperglycemic Crises

• Two main types of hyperglycemic crises are diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS):

• DKA presents acutely without altered consciousness but includes symptoms like nausea, vomiting, abdominal pain, polyuria, and polydipsia.

• HHS develops more slowly with altered consciousness often occurring alongside other illnesses; both conditions can exhibit mixed features in some patients.

Diagnosis Criteria for Hyperglycemic Crises

• For DKA:

• Blood glucose >200 mg/dL,

• Evidence of ketosis (ketonemia/ketonuria),

• Metabolic acidosis indicated by arterial blood gases showing bicarbonate <18 mEq/L.

For HHS:

• Severe hyperglycemia (>600 mg/dL),

• Hyperosmolality (>300 mOsm/kg),

• Absence of ketonemia/acidosis.

If criteria for both are met, it indicates mixed characteristics in up to one-third of cases.

Management Strategies for Hyperglycemic Crises

• Upon diagnosing a crisis:

• Initiate intravenous fluids immediately using crystalloids (balanced solutions or saline).

• Insulin therapy will follow based on severity and clinical guidelines.

Insulin Management in Diabetic Patients

Insulin Administration Guidelines

• Insulin should not be initiated until potassium levels are assessed; if potassium is below 3.5 mEq/L, it must be replenished before starting insulin.

• For potassium levels above 5 mEq/L, insulin can be started with monitoring every 2 hours; for levels between 3.5 and 5, administer potassium alongside saline solution.

Treatment of Diabetic Ketoacidosis (DKA)

• In moderate to severe DKA or hyperosmolar hyperglycemic state, intravenous insulin is administered at a dose of 0.1 units/kg as a bolus followed by continuous infusion.

• For mild DKA, subcutaneous insulin can be given at a bolus of 0.1 units/kg and then continued at 0.2 units/kg every two hours until glucose drops below 250 mg/dL.

Resolution Criteria for DKA

• Resolution criteria include improvement in pH, normalization of bicarbonate levels, absence of acetonemia, and osmolarity below 200 mOsm/L with urine glucose under 250 mg/dL.

Transitioning from IV to Subcutaneous Insulin

• When transitioning from IV to subcutaneous insulin, calculate the basal-bolus regimen based on higher doses for hospitalized patients; typically use half the total daily dose for basal administration.

• Maintain the IV infusion for an additional two hours after administering basal insulin to prevent hyperglycemic crisis due to delayed action.

Understanding Hypoglycemia Risks

Factors Contributing to Hypoglycemia

• Various risk factors include advanced age, female sex, glycemic variability, polypharmacy, and chronic kidney disease which increase susceptibility to hypoglycemia.

Symptoms of Hypoglycemia

• Symptoms are categorized into neurogenic (autonomic symptoms like sweating and palpitations) and neuroglycopenic (altered consciousness due to energy deficiency in the brain).

Diagnosing Hypoglycemia in Diabetes

• Diagnosis involves measuring blood glucose: level one is between 70–54 mg/dL; level two is below 54 mg/dL; level three includes any low glucose with altered mental status requiring assistance.

Managing Hypoglycemia

Prevention Strategies

• Continuous glucose monitoring helps identify patients prone to hypoglycemia; it's crucial since hypoglycemia poses greater mortality risk than hyperglycemia.

Treatment Protocol

• The "15 Rule" suggests administering 15 grams of glucose or dextrose and rechecking blood sugar after 15 minutes; oral administration preferred unless contraindicated.

Chronic Complications in Diabetes

Diabetic Kidney Disease

Understanding Chronic Kidney Disease and Its Management

Overview of Nephron Preservation

• The focus is on preserving remaining nephrons in patients with chronic kidney disease (CKD). It is noted that nephropathy does not always correlate with retinopathy, particularly in Type 1 diabetics.

Evaluation and Diagnosis of CKD

• CKD evaluation involves assessing renal function through albumin-to-creatinine ratio and creatinine levels to estimate glomerular filtration rate (GFR), typically done annually.

• Accurate diagnosis requires two to three samples of albuminuria over a period of three to six months, as transient proteinuria can occur. CKD diagnosis necessitates evidence of alteration for more than three months.

Identifying Complications and Referrals

• In cases where only albuminuria is present without GFR decline, further monitoring is essential. Rapid declines or sudden increases in proteinuria warrant referral to a nephrologist.

• If the patient has Type 1 diabetes without retinopathy but shows concerning symptoms, additional studies or even biopsy may be necessary.

Treatment Strategies for Diabetic Kidney Disease

• Glycemic control is crucial for preventing diabetic kidney disease. If established, treatment includes medications like ICARUS 2 aimed at reducing albuminuria by over 30%.

• Medications such as SGLT2 inhibitors are recommended; if not tolerated, calcium antagonists may provide antiproteinuric effects.

Dietary Recommendations and Monitoring

• Patients with GFR below 30 should limit protein intake to less than 0.8 g/kg/day and sodium intake ideally under 2.3 g/day (approximately 5g salt).

• Early referral to nephrology is advised if GFR declines below 30 or if the cause remains uncertain due to potential complications like electrolyte imbalances and hypertension.

Comprehensive Patient Management Approaches

• Lifestyle changes are emphasized alongside pharmacological treatments including SGLT2 inhibitors and RAAS inhibitors for managing cardiovascular risks associated with CKD.

• The use of GLP1 analogues has been included in managing diabetic kidney disease based on recent studies highlighting their benefits.

Retinal and Neuropathic Complications Screening

• Regular screening for retinopathy every two years using dilated eye exams; pregnant women require quarterly assessments due to increased risk.

• Annual neuropathy screenings involve various tests (e.g., pinprick sensation, temperature sensitivity), focusing on both small and large fiber neuropathies.

Managing Neuropathic Pain

• For neuropathic pain management, options include gabapentinoids, tricyclic antidepressants, while opioids are deemed ineffective.

Foot Care in Diabetic Patients

• Annual foot examinations are critical for detecting signs of neuropathy or peripheral arterial disease; referrals to podiatrists are necessary when issues arise.

Management of Ulcers and Special Populations in Diabetes Care

Strategies for Ulcer Management

• Emphasizes the importance of reducing pressure on severe ulcers, suggesting methods like debridement of necrotic tissue and revascularization for ischemic wounds.

• Discusses advanced management techniques such as negative pressure therapy, hyperbaric chambers, and cellular matrices to treat complex ulcer cases.

Considerations for Elderly Patients

• Highlights the need for individualized care plans based on the health status of elderly patients, with hemoglobin A1c targets potentially ranging from 7% to no specific target.

• Stresses the importance of screening for geriatric syndromes (e.g., dysphagia, dementia) and avoiding hypoglycemia in older adults.

The 4 Ms Strategy

• Introduces the "4 Ms" strategy: evaluating Mentality, Mobility, Medications, and what matters most to the patient—balancing glycemic control with quality of life.

Simplifying Diabetes Management

• Suggests simplifying medication regimens for elderly patients by considering their insulin types (basal vs. prandial), aiming to minimize complexity while ensuring effective treatment.

Pregnancy and Diabetes Management

• Advises women with diabetes to undergo preconception evaluations to assess glycemic control before pregnancy; emphasizes monitoring during early pregnancy.

• Outlines that gestational diabetes screening should occur between 24 to 28 weeks; if diagnosed, a follow-up test is necessary within 4 to 12 weeks post-diagnosis.

Implications of Gestational Diabetes

• Notes that gestational diabetes can lead to worse maternal and fetal outcomes; thus regular screening every three years is recommended post-pregnancy.

Insulin Sensitivity Changes During Pregnancy

• Describes how insulin sensitivity increases in early pregnancy but may decline later on, leading to potential gestational diabetes or challenges in managing existing diabetes.

Diagnostic Approaches for Gestational Diabetes

• Recommends a one-step approach using an oral glucose tolerance test (OGTT), which effectively predicts maternal-fetal outcomes when diagnosing gestational diabetes.

Importance of Preconception Glycemic Control

• Stresses that women planning pregnancy should aim for an HbA1c below 6.5% prior to conception; highlights potential interactions between GLP1 analogues and oral contraceptives.

Postpartum Considerations

• Discusses dietary management primarily during postpartum periods; if control isn't achieved through lifestyle changes, insulin therapy may be required.

Monitoring After Delivery

Diabetes Management and Genetic Considerations

Key Goals in Diabetes Management

• The target for hemoglobin A1c (HbA1c) should be less than 6%, with specific fasting and postprandial glucose goals guiding pharmacological management.

• In cases where insulin is required, it becomes the new target for managing diabetes effectively.

Understanding Genetic Forms of Diabetes

• Neonatal diabetes occurs before six months due to mutations in potassium channel genes or insulin-related genes; it can be transient or permanent.

• Maturity Onset Diabetes of the Young (MODY) typically appears after six months but before 25 years, often presenting with stable hyperglycemia without ketoacidosis.

Importance of Family History in Diagnosis

• MODY is usually inherited in an autosomal dominant pattern, making family history crucial for diagnosis; common types include Type 2, Type 3, and Type 1.

• Accurate diagnosis can influence treatment decisions, such as discontinuing certain medications or using sulfonylureas for MODY type 1.

Screening Recommendations for Specific Conditions

• Patients with acute pancreatitis should undergo diabetes screening three to six months post-episode and annually if chronic pancreatitis develops.

• Avoid GLP-1 analogues and DPP-4 inhibitors in patients with pancreatitis due to documented risks; early insulin initiation may be necessary.

Monitoring Guidelines for Cystic Fibrosis Patients

• Annual diabetes screening is recommended starting at age ten for cystic fibrosis patients using blood glucose measures rather than HbA1c.

Post-transplant Diabetes Considerations

• Post-transplant diabetes (NODAT/PTDM) requires annual screening after establishing stable immunosuppression (45 days).

• If a patient develops diabetes post-transplant, it does not necessitate changing their immunosuppressive therapy; management focuses on controlling blood sugar levels while maintaining organ health.